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Abstract Background and aims:
Anti-TNF-a antibodies are very ef-
fective in the treatment of acute
Crohn’s disease, but are limited by
the decline of their effectiveness
after repeated applications. The
stinging nettle leaf extract, IDS 30,
is an adjuvant remedy in rheumatic
diseases dependent on a cytokine
suppressive effect. We investigated
the effect of IDS 30 on disease ac-
tivity of murine colitis in different
models. Methods: C3H.IL-10/ and
BALB/c mice with colitis induced by
dextran sodium sulphate (DSS) were
treated with either IDS 30 or water.
Mice were monitored for clinical
signs of colitis. Inflammation was
scored histologically, and faecal
IL-1b and mucosal cytokines were
measured by ELISA. Mononuclear
cell proliferation of spleen and
Peyer’s patches were quantified by
3H-thymidine. Results: Mice with
chronic DSS colitis or IL-10/
mice treated with IDS 30 clinically
and histologically revealed signifi-
cantly (p<0.05) fewer signs of colitis
than untreated animals. Furthermore,
faecal IL-1b and mucosal TNF-a
concentrations were significantly
lower (p<0.05) in treated mice.
Mononuclear cell proliferation after
stimulation with lipopolysaccharide
was significantly (p<0.001) reduced
in mice treated with IDS 30.
Conclusions: The long-term use of
IDS 30 is effective in the preven-
tion of chronic murine colitis. This
effect seems to be due to a decrease
in the Th1 response and may be a
new therapeutic option for prolong-
ing remission in inflammatory
bowel disease.
Keywords Inflammatory bowel
disease · IDS 30 · Murine colitis ·
TNF-a
Introduction
Until now, the pathogenesis of inflammatory bowel dis-
ease (IBD) is not totally understood. However, in Crohn’s
disease (CD), genetic, immunological and environmental
factors clearly play an important role. One important
concept is the imbalance between T-helper (Th) cell
subsets with an overreaction of Th1 cells. Various pro-
inflammatory cytokines (especially TNF-a) are secreted
by the mucosa of the intestinal tract during the disease [1].
Furthermore, the cells producing TNF-a, as well as the
TNF-a concentration in stools, were enhanced [2, 3].
Based on these results, agents have been developed to
suppress TNF-a as a new approach in the therapy of
CD. An efficient therapeutic strategy for patients with CD
is the intravenous application of anti-TNF-a antibodies
(infliximab). Infliximab has been shown to be effective in
the treatment of refractory luminal CD, as well as in the
treatment of fistulae [4, 5]. Some patients, however, are
refractory to immune suppressive treatment and need re-
peated infusions of infliximab for maintenance of remis-
sion [6]. In addition to the high costs of this therapy, some
patients develop side effects such as infusion reactions or
infectious complications [7–9]. Finally, a loss of effec-
tiveness has been observed after repeated applications
[10]. Another anti-TNF-a approach is the therapy with
10
soluble receptors (e.g. etanercept). This recombinant re-
ceptor/Fc fusion protein binds to human TNF-a, but a
placebo-controlled trial revealed no significant clinical
benefit in CD [11]. In the search for further anti-TNF-a
remedies, a few open-label trials have been published
using the teratogen thalidomide, which inhibits the pro-
duction of TNF-a [12–14]. This medication, however, is
rejected by the majority of patients because of its side
effects. Therefore, it is necessary to evaluate further
strategies leading to a modulation of cytokine expression
such as novel anti-TNF-a strategies [15, 16].
In this paper we investigate the effects of IDS 30, a
stinging nettle leaf extract that is a well-known adjuvant
drug in the continuous therapy of rheumatic diseases.
Stinging nettle leaf extract was able to reduce pain in the
joints and 26% of patients were able to withdraw their
non-steroidal anti-rheumatic (NSAR) medications. IDS 30
is a standardised extract of stinging nettle leaves that po-
tently suppresses TNF-a and IL-1b [17, 18]. The effects
are at least in part due to an inhibitory effect on NF-kB.
Inhibition of NF-kB was not mediated by a direct modi-
fication of DNA binding, but rather by preventing degra-
dation of its inhibitory subunit IkB-a [19]. Furthermore, it
has been shown that these extracts mediate a switch in
cytokine patterns derived from T-helper cells [20]. IDS 30
(Strathmann AG; Hamburg, Germany) is a specially de-
veloped lipophilic stinging nettle leaf extract with high
concentration of 13-S-hydroxy-9Z, 11E, 15Z-octadeca-
trienoic acid (13-HOTE). This oxylipin has been identified
as a cytokine-suppressive agent in stinging nettle leaves.
In CD, the therapeutic options for maintenance therapy
are still limited and most of them are characterised by
potential side effects. Thus, we investigated the preven-
tive and therapeutic effect of the orally applied anti-
TNF-a active medication IDS 30 on murine colitis. The
following experimental IBD models were used: interleu-
kin-10 gene-deficient mice (IL-10/) developing a spon-
taneous colitis, and when orally administrated with the
dextran sodium sulphate salt (DSS induces acute and
chronic colitis) [21]. These models are widely accepted as
a reproducible mucosal colonic inflammation in mice
[22].
Materials and methods
Materials
The stinging nettle leaf extract IDS 30 (Hox alpha) was kindly
provided by Strathmann AG, Germany. The drug was administered
at a final concentration of 0.5 mg/ml in drinking water. The daily
uptake of IDS 30 in mice corresponded to the dose used in humans
for the treatment of rheumatoid arthritis.
Animals
Forty-two BALB/c mice were obtained from Harlan (Horst, The
Netherlands). Sixteen homozygous 4-week-old interleukin 10 gene-
deficient mice (IL-10/), generated on a C3H/HeJBir genetic
background (C3H.IL-10/), were housed and bred under specific
pathogen-free conditions (individually-ventilated cages, IVC). All
provisions for the facility were sterilised by autoclaving. All animal
experiments were approved by the Swiss authorities.
Five 8-week-old BALB/c mice were treated with 3.5% DSS salt
(ICN Biomedicals; Aurora, OH, USA) for 5 days to induce an acute
chemical colitis. Treatment with IDS 30 was started for the 4 days
following the induction of colitis, and the mice were sacrificed on
day 9.
Eight 8-week-old BALB/c mice were treated with the prepared
IDS 30 drinking solution or water for 7 days, and another set of
eight mice received water as a control. On day 8, 3.5% DSS was
administered for 5 days to induce an acute chemical colitis.
Treatment with IDS 30 was continued for 4 days following the
induction of colitis, and the mice were sacrificed on day 16.
The chronic DSS colitis was induced by three cycles of 3% DSS
for 4 days. The DSS phase was interrupted by periods of 1 week’s
treatment with IDS 30 (or water) each time, and a final treatment
with IDS 30 (or water) for the last week. Again, eight mice were
treated with IDS and eight mice with water as a control in these
experiments.
Eight 4-week-old C3H.IL-10/ mice without clinical signs of
colitis received either the water with 0.5 mg/ml IDS 30 or water
alone for 10 weeks, and were sacrificed on day 70.
Monitoring
The drinking volume, weight and clinical signs of colitis for each
mouse were monitored four times a week (redness of the anus,
ulcerations of the anus, weight loss, diarrhoea and bloody diar-
rhoea).
Histological injury grading
All mice were sacrificed by CO2 inhalation. Longitudinal halves of
colons and caeca were taken in their entirety; the length was
measured and fixed in 4% phosphate-buffered formalin. Samples
were embedded in paraffin in toto and sectioned at 5 mm. Sections
were stained with H&E and the slides were scored double-blinded
by two different experts (M.M. and B.F.) as previously described
[23]. Briefly, the histological score ranged from grade 0 to 3 (Ta-
ble 1). The intestinal inflammation of each mouse was scored at the
proximal, middle and distal colon, and the scores for each section
were computed, resulting in a range from 0 to 9. Furthermore, the
intestinal inflammation from the caecum was scored separately and
ranged from 0 to 3.
Faecal sample preparation
Faecal samples were collected and weighed. Samples were ho-
mogenised in 3 ml/0.1 g stool weight in a solution of 1 mg/ml soy
trypsin inhibitor and 1 mg/ml PMSF (phenylmethylsulphonyl flu-
oride from Sigma; Buchs, Switzerland) in PBS (phosphate-buffered
saline, Sigma). Supernatants were collected after centrifugation at
10,000 g for 15 min, sterile filtered and stored at 70C prior to
testing. IL-1b concentrations were measured by sandwich ELISA
using a commercial test system (R&D Systems; Abingdon, UK).
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Mucosal cytokine secretion
Longitudinal halves of colons were removed from the control
and treated animals, put in cold Hanks-balanced salt solution with-
out calcium and magnesium (HBSS, Life Technologies; Basel,
Switzerland), cut into 2- to 4-mm squares and resuspended in
complete Roswell Park Memorial Institute (RPMI) medium. Mu-
cosal pieces were then incubated at 37C in 5% CO2 in the presence
or absence of 2 mg/ml lipopolysaccharide (LPS from E. coli, Se-
rotype 055:B5, Sigma, Switzerland). After 6 h, supernatants were
collected for measurement of TNF-a and IL-1b and stored at 70C
prior to testing. Cytokine secretion was measured using commercial
ELISAs (BD Biosciences Pharmingen; Basel, Switzerland; R&D
Systems).
Isolation of mononuclear cells
Peyer’s patches and spleens were taken, placed in HBSS, washed,
strained through a mesh sieve (40-mm pores) and centrifuged for
8 min at 1,800 rpm. The supernatant was removed and the spleen
pellet was resuspended in erythrocyte lysis buffer (ACK-buffer)
and cells washed in HBSS three times before reconstitution to
2106 cells/ml in complete RPMI medium, supplemented with 5%
heat-inactivated foetal bovine serum and 100 U/ml antibiotic/anti-
mycotic solution (Life Technologies).
Proliferation assay for mononuclear cells
Mononuclear cells were cultured in complete RPMI medium.
Mononuclear cells (2106/ml) were co-cultivated either with 1–
10 mg/ml LPS, 3 mg/ml of the cell mitogen Concanavalin A (Con A,
Bhringer; Mannheim, Germany) or 5 mg/ml anti-CD3 (Pharmin-
gen), and incubated for 4 days. Proliferation was determined by 3H-
thymidine incorporation (Amersham; Little Chalfont, UK). Cells
were pulsed with 3H-thymidine for the final 18 h and harvested
(Skatron; Lier, Norway). Incorporated 3H-thymidine was quantified
by scintillation counting (Beckmann; Fullerton, CA, USA).
Statistical analysis
The results were expressed as mean € standard error of the mean.
The significance of the difference in means was determined by the
unpaired, two-tailed Student’s t-test (GraphPadPrism 3.0).
Results
Ameliorative effect of the stinging nettle leaf extract
IDS 30 on disease activity of chronic DSS colitis
The clinical effects of a daily oral treatment with IDS 30
were compared with those in untreated controls in a DSS-
induced chronic and acute colitis model. Since a thera-
peutic effect of IDS 30 in rheumatic diseases was only
seen after several weeks of treatment, we investigated the
chronic DSS colitis model. As shown in Fig. 1a, in the
chronic DSS model, no significant difference in weight
over the time of the experiment was observed when
comparing mice treated with IDS 30 with untreated mice.
However, during the DSS cycles, the loss of weight was
earlier and more severe in the control compared with the
IDS 30 treatment group with increasing evidence in the
repeated DSS phases (not significant). Only the water-
treated group (25%) and not the mice treated with IDS 30
showed more frequently clinical signs of colitis (redness
and ulcerations of the anus, bloody diarrhoea; p<0.05).
These observations were supported by the significantly
reduced colon length in the water-treated group compared
with mice receiving IDS 30 (7.3 vs. 8.2 cm, p<0.05), and
were confirmed by a non-significant, more severe histo-
logical score in untreated mice. The mice treated with
IDS 30 were scored with 4.25€0.25 for the colon, whereas
the control group averaged over 4.75€0.25 (p=0.20). The
caeca were scored with 2.00€0.0 vs. 2.5€0.5 (Table 2).
Amelioration of disease in IL-10/ mice
In a further experiment on chronic murine colitis over
a 10-week period, we applied IDS 30 to 4-week-old
C3H.IL-10/ mice while a control group was treated
with water as a placebo. We found a parallel gain in
weight in both groups (Fig. 1b). In 29% of the placebo
group, we observed clinical signs of colitis, such as red-
ness of the anus and perianal ulcerations; the same ob-
servations were made in only 14% of the mice treated
with IDS 30. Significant discrepancies were measured in
the colon length (8.4 vs. 7.1 cm; p<0.05) and histological
injury grading (p<0.05). The colons of mice treated with
IDS 30 were scored with 2.5€0.5, whereas the control
Table 1 Histopathological score
Score Characteristics
Grade 0 No change from normal tissue
Grade 1 Mild mucosal hyperplasia; inflammation and/or fibrosis in the lamina propria mucosae; occasional erosions and/or small ulcers
(involving up to a total of 20 crypts)
Grade 2 Moderate mucosal hyperplasia; multifocal areas of inflammation and/or fibrosis extending into the tunica submucosa and
sometimes transmural; crypt abscesses; erosions and ulcers (involving up to a total of 40 crypts)
Grade 3 Severe mucosal hyperplasia; diffuse areas of inflammation and/or fibrosis extending into the tunica muscularis; crypt abscesses;
erosions and ulcers (involving more than a total of 40 crypts)
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group averaged over 4.75€0.25. Caeca were scored with
2.0€0.0 vs. 2.75€0.25 (Fig. 2; Table 2).
IDS 30 is not effective in the prevention
or amelioration of acute colitis
After the demonstration of the beneficial effect of IDS 30
on chronic murine colitis, we investigated the effect of
this component in the acute DSS model. We observed a
similar progression in weight in the groups treated and
untreated with IDS 30 (Fig. 1c). Neither the clinical signs
of colitis nor the colon length differed significantly in
either group (7.0 cm [IDS 30] vs. 6.8 cm [control]; Ta-
ble 2). We found a non-significant, more severe histo-
logical score in untreated mice. The colon scores were
3.6€0.2 in the IDS 30 group vs. 4.00€0.0 in the water
group, and 2.4€0.25 vs. 2.6€0.25 for the caecum.
Fig. 1 a Increase in the weight of BALB/c mice and C3H/He
JBir.IL-10/ mice treated with IDS 30 compared with those
treated with water. In the chronic dextran sodium sulphate (DSS)
model, colitis was induced after 1 week’s pre-treatment with
IDS 30 by three cycles of 3% DSS for 4 days interrupted by a
period of 1 week’s treatment with IDS 30 (or water). b Increased
weight of the C3H.IL-10/ mice treated for 10 weeks with IDS 30
versus water. In the acute DSS model, c BALB/c mice were treated
with IDS 30 after colitis had been established or d mice were pre-
treated with IDS 30 or water for 1 week before the induction of
colitis with DSS. Afterwards, 3.5% DSS was applied for 5 days,
and the treatment was continued for 4 days (c, d). Note that n=5
BALB/c mice in experiment (c), n=8 BALB/c mice per group in a,
d, and n=8 IL-10 knockout mice per group in b
Table 2 Colon length and histological score of treated and untreated animals. DSS dextran sodium sulphate
IDS 30-treated
mice; colon
length in cm
(mean € SEM)
Water-treated
mice; colon
length in cm
(mean € SEM)
IDS 30-treated
mice; score/
colon
(mean € SEM)
Water-treated
mice; score/
colon
(mean € SEM)
IDS 30-treated
mice; score/
caecum
(mean € SEM)
Water-treated mice
score/caecum
(mean € SEM)
Chronic DSS model
(BALB/c mice)
8.2€0.4* 7.3€0.2 4.25€0.25 4.75€0.25 2.00€0.0 2.5€0.5
C3H.IL-10/ mice 8.4€0.3* 7.1€0.3 2.5€0.5* 4.75€0.25 2.00€0.0* 2.75€0.25
Acute DSS model
(BALB/c mice)
therapy
7.0€0.2 6.8€0.4 3.6€0.2 4.00€0.0 2.4€0.25 2.6€0.25
Acute DSS model
(BALB/c mice)
prevention
7.1€0.3 6.9€0.3 3.25€0.25 4.00€0.0 2.25€0.25 2.75€0.25
* p<0.05
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When mice were pre-treated for 1 week with IDS 30 or
water prior to the DSS application, we found less weight
loss in the mice treated with IDS 30 during the DSS phase
(not significant) than those in the water-treated group
(Fig. 1d). There was no difference in the drinking volume
between the two groups. At the end of the DSS feeding,
we observed clinical signs of colitis (redness of the anus,
diarrhoea and bloody diarrhoea) less frequently in the
group treated with IDS 30 than in the control group (38
vs. 50%). Neither the clinical signs of colitis nor the colon
length differed significantly in either group (7.1 cm vs.
6.9 cm [pre-treatment regimen]; Table 2). We found a
non-significant, more severe histological score in un-
treated mice. The animals pre-treated with IDS 30 were
scored 3.25€0.25 vs. 4.00€0.0 in the water group for the
colon, and 2.25€0.25 vs. 2.75€0.25 for the caecum (Ta-
ble 2).
Treatment with IDS 30 reduces faecal
IL-1b concentration
To verify the disease activity during murine colitis, stool
samples were collected at different times, and IL-1b was
measured using ELISA. We observed similar concentra-
tions in BALB/c- and in C3H.IL-10/ mice prior to
treatment (Fig. 3a–c). In the chronic DSS model, there
were non-significantly higher IL-1b concentrations in
untreated than in treated mice after a period of 14 days
(meanwater 82 pg/ml, meanIDS 30 8 pg/ml; p=0.17; Fig. 3b).
After more than 5 weeks of treatment, we observed a
significant difference between the group treated with
IDS 30 and the untreated group (meanwater 634 pg/ml,
meanIDS 30 229 pg/ml; p=0.043; Fig. 3a). In C3H.IL10/
mice we detected significantly (p=0.02) higher levels of
IL-1b at day 70 in faecal samples of the untreated group
than in the group of mice that received IDS 30 (meanwater
472 pg/ml, meanIDS 30 51 pg/ml; Fig. 3b).
In the acute DSS model, higher concentrations of
IL-1b at day 11 were measured in the placebo group
(meanwater 260 pg/ml) during acute colitis than in the
group treated with IDS 30 (meanIDS 30 220 pg/ml; not
significant; p=0.25; Fig. 3c).
Reduction of mucosal TNF-a and IL-1b production
after IDS 30 treatment in BALB/c mice
To investigate the influence of IDS 30 on intestinal
cytokine production, colons of treated and untreated
BALB/c mice from the chronic and acute DSS models
were removed to obtain mucosal organ cultures that
were cultured in the presence or absence of 2 mg/ml
LPS. In the chronic DSS model, there were significantly
higher levels of TNF-a in mucosal supernatants of colon
(p=0.035) of placebo than in animals treated with IDS 30
after stimulation with LPS (Fig. 4a). Without stimulation,
lower concentrations of the pro-inflammatory cytokine
TNF-a were detected in supernatants of mucosal organ
cultures from mice of the acute DSS model receiving
IDS 30 than in untreated animals. However, after stim-
ulation with LPS, no difference was observed between
the two groups (Fig. 4b). The investigation of mucosal
IL-1b concentrations revealed no differences between
treated and untreated animals under baseline conditions.
However, the mice treated with IDS 30 in the pres-
ence of LPS had significantly lower levels of IL-1b
in comparison to the water-treated group of mice.
These observations were made in the chronic DSS model
(p=0.044) as well as in the acute DSS model (p=0.042;
Fig. 4c, d).
Fig. 2 Histological sections from C3H.IL-10 knockout mice (H&E,
10). The histology of mice treated with IDS 30 was scored with
2.50€0.50, whereas the control group averaged over 4.75€0.25. a
Proximal colon of an IL-10-deficient mouse treated with IDS 30
with normal appearance. b Proximal colon of a water-treated IL-10-
deficient mouse showing severe inflammatory cell infiltration in the
lamina propria and submucosa (n=8 mice per group)
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Proliferation of mononuclear cell
Splenic mononuclear cells from BALB/c mice of the
chronic DSS model treated with IDS 30 proliferated fewer
splenocytes after stimulation with LPS compared with
untreated mice (Fig. 5a). We found a significant dif-
ference after stimulation with 1 mg/ml (*p=0.0272) and
10 mg/ml LPS (**p=0.0038). Similar results were ob-
tained in Peyer’s patches after stimulation with 1 mg/ml
(***p=0.0007) and 10 mg/ml LPS (**p=0.0019). Com-
paring T-cells of BALB/c mice treated with IDS 30 with
those of untreated BALB/c mice, we found no difference
in the proliferative response after stimulation with either
anti-CD3 or Con A (data not shown). In order to inves-
tigate whether the IDS 30 itself has any influence on
the proliferative response, we stimulated mononuclear
cells from IDS 30-treated and -untreated BALB/c and
C3H.IL-10/ mice using different concentrations (1–
10 mg/ml) of IDS 30. No proliferation could be detected
(data not shown).
Discussion
Inflammatory bowel disease and rheumatoid arthritis have
partially common pathomechanisms and several medical
therapies such as steroids and infliximab are effective in
both diseases. IDS 30 is approved as an adjuvant therapy
of rheumatic diseases in Germany. This paper has de-
scribed the biological efficacy of IDS 30 on colitis in
three different experimental mouse models for IBD. We
found a substantial effect of IDS 30 in two models of
chronic colitis. The limited effect of IDS 30 in the treat-
ment of acute colitis may be due to the short duration of
treatment with this substance. This effect was also seen in
clinical studies with patients suffering from arthritis in
which the clinical benefit was detectable after a duration
of treatment of several weeks. The clinical observations in
this study were confirmed by the measurement of IL-1b
in stools, a widely used disease activity marker for murine
colitis [24]. We found significantly higher IL-1b con-
centrations in untreated animals than in treated ones.
Several mechanisms of the stinging nettle leaf extract,
IDS 30, have been discussed. This includes the suppres-
sion of cytokine production via an inhibition of NF-kB
activation by IDS 30 [19]. In IBD models, the inhibition
of NF-kB or the pro-inflammatory cytokine TNF-a by an
antisense oligonucleotide strategy, led to an improvement
in the disease [25, 26]. The effect of IDS 30 on NF-kB
in the context of IBD has not been investigated so far.
Furthermore, IDS 30 leads to a suppression of matrix
metalloproteinases as shown in chondrocytes in vivo. It is
known that the elevation of these metalloproteinases plays
a certain role in IBD [27, 28], but the effect of IDS 30 in
Fig. 3 Stool samples for IL-1b determination were collected prior,
during and after treatment with IDS 30 or water. IL-1b concen-
trations were determined by ELISA. a In the chronic DSS model,
the IL-1b levels were significantly lower in the mice treated with
IDS 30 at the end of the experiment. b IL-1b concentrations in
faecal samples from untreated C3H.IL-10/ mice compared with
IDS 30-treated animals (*p<0.05). c IL-1b concentrations in faecal
samples from IDS 30 and water-treated BALB/c mice prior treat-
ment, in the DSS phase and 5 days after the DSS application in the
acute DSS model (n=8 mice per group)
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this context remains to be evaluated. A third important
mechanism of IDS 30 may be the decrease in the secre-
tion of pro-inflammatory cytokine TNF-a in the intestinal
mucosa. An imbalance of a Th1 and Th2 reaction with a
preponderance of a Th1 reaction in CD is a widely ac-
cepted pathogenic concept. Madsen et al. have shown that
colitis in IL-10/ mice is associated with high levels of
mucosal TNF-a. When the mice were housed under germ-
free conditions, the disease was prevented and the mu-
cosal TNF-a ranged within normal levels [29]. These
findings suggest that the IL-10/ colitis is a result of a
Th1-triggered immune response to the mucosal micro-
flora. Furthermore, the clinical data on the effect of an
anti-TNF therapy support the importance of TNF-a in the
pathogenesis of CD [30, 31]. In another study, it was
shown that stinging nettle leaf extract is able to inhibit a
Th1 reaction in vitro. The production of IL-2 and IFN-a
proteins as well as mRNA by mononuclear cells was in-
hibited in a dose-dependent manner [20]. Furthermore, in
vitro data on macrophages showed that TNF-a and IL-1b
secretion after LPS stimulation were reduced by the ad-
dition of a stinging nettle leaf extract of up to 99% in a
dose-dependent manner [18]. This study clearly demon-
strates the downward regulatory effect of IDS 30 on the
Th1-triggered immune response in BALB/c as well as in
C3H/HeJBir.IL-10/ mice after stimulation with LPS.
We detected a significant decrease in IL-1b as well as less
TNF-a secretion in the supernatants of the intestinal
mucosa in treated animals. In vitro, this effect is mediated
by a reduced maturation of dendritic cells and their ex-
pression of CD83 and CD86, leading to a reduced T-cell
response. One of the most potent inducers of pro-in-
flammatory cytokines is LPS, the most common patho-
gen-associated molecular pattern. LPS isolated from E.
coli is well characterised, it signals through the toll-like
receptor complex and induces Th cells to secrete high
levels of pro-inflammatory cytokines [32]. In this study,
the mononuclear cells of spleens and Peyer’s patches
from mice treated with IDS 30 proliferated less after
stimulation with LPS from E. coli than those from water-
treated mice. This indicates the suppression of a Th1-type
reaction by IDS 30. Our in vivo models clearly show a
reduced mucosal TNF-a and IL-1b secretion triggered by
the application of IDS 30 during long-term treatment. In
humans, increased secretion of IL-1b and TNF-a is
commonly used as a predictive marker for acute relapse.
Schreiber et al. demonstrated the positive correlation
between high secretion of the pro-inflammatory cytokines
TNF-a or IL-1b from lamina propria mononuclear cells
and relapse in patients with CD [33].
Until now, the therapeutic goal in the therapy of IBD is
the remission of clinical symptoms as well as the healing
of the mucosal inflammation [34]. The therapeutic tools
to prolong remission and to reduce mucosal inflammation
Fig. 4 a, b Mucosal TNF-a and c, d IL-1b secretion in BALB/c
mice at the end of the IDS 30 DSS treatment. b Under basal con-
ditions, lower concentrations of the pro-inflammatory cytokine
TNF-a were detected in mucosal organ cultures from DSS-treated
mice, which received IDS 30 vs. placebo (acute DSS model). a
After stimulation with 2 mg/ml lipopolysaccharide (LPS), signifi-
cantly higher levels of TNF-a were detected in the supernatants of
the colon of placebo than in IDS 30-treated animals in the chronic
DSS model. c, d For the IL-1b secretions, no difference was ob-
served under baseline conditions, whereas in the presence of LPS,
significantly lower levels of IL-1b were observed in IDS 30-treated
mice from the chronic as well as from the acute DSS model (n=8
mice per group). *Significant difference (p< 0.05) between the
groups
16
References
1. Van Deventer SH (1997) Tumour ne-
crosis factor and Crohn’s disease. Gut
40:443–448
2. Breese EJ, Michie CA, Nicholls SW,
Murch SH, Williams CD, Domizio P et
al (1994) Tumor necrosis factor alpha-
producing cells in the intestinal mucosa
of children with inflammatory bowel
disease. Gastroenterology 106:1455–
1466
3. Braegger CP, Nicholls SW, Murch SH,
Stephens S, MacDonald TT (1992)
Tumour necrosis factor alpha in stool as
a marker of intestinal inflammation.
Lancet 339:89–91
4. Targan SR, Hanauer SB, van Deventer
SJ, Mayer L, Present DH, Braakman T
et al (1997) A short-term study of chi-
meric monoclonal antibody cA2 to tu-
mor necrosis factor alpha for Crohn’s
disease. Crohn’s disease cA2 Study
group. N Engl J Med 337:1029–1035
are still limited. In CD, the most efficient therapies
comprise immune suppressive therapies such as azathio-
prine, 6-mercaptopurine and methotrexate. These sub-
stances may maintain about 60% of the patients in re-
mission [35]. The repeated application of the anti-TNF
antibody infliximab is mainly limited by its costs, the
intravenous application, infection complications and the
possible loss of efficacy following repeated applications.
The need for further anti-TNF-a drugs is undisputed, as
shown in many recently published experimental studies
[26, 36]. Our data show the TNF-a-suppressive effect of
IDS 30. However, it could not be compared with inflix-
imab in terms of efficacy and time of response. In arthritis
patients, though, this medication is well tolerated. Our
data were much more impressive in the chronic murine
colitis models than in the acute colitis model. Apparently,
IDS 30 needs several days for a clinical effect to be seen.
This is supported by the fact that the LPS-stimulated
TNF-a release decreased during the IDS 30 treatment.
The basal TNF-a was not affected by the treatment with
IDS 30, as already described in another study of TNF-a
suppression [26]. In that study, the antisense TNF-a
suppression was effective in the acute DSS model, but
only if higher concentrations than in the chronic colitis
model were used. Another explanation might be the dif-
ferent pathophysiological effects caused by acute versus
chronic DSS application. Acute DSS colitis is indepen-
dent of lymphocytes, mainly triggered by toxic effects of
DSS on epithelial cells of the colon and can be induced in
SCID-mice, whereas in chronic DSS colitis, immunologic
mechanisms are involved [37]. Our data support the hy-
pothesis of the beneficial effect by TNF-a inhibition on
preventing disease in different models of experimental
IBD.
In conclusion, the use of IDS 30 in the experimental
treatment of IBD is effective in the prevention and ame-
lioration of chronic murine colitis in DSS-treated BALB/c
and in C3H.IL-10/ mice. This is the first study to
demonstrate the beneficial immunomodulatory effect of
IDS 30 on experimental IBD in vivo. Therefore, IDS 30
appears to be a new candidate for maintenance therapy in
IBD, which needs to be shown in controlled studies with
patients.
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Fig. 5 Effect of IDS 30 on the proliferative response of mono-
nuclear cells in treated and untreated BALB/c mice from the
chronic DSS model. Mononuclear cells from the spleen and Peyer’s
patches were isolated from mice treated with IDS-30 or water
and stimulated with LPS. The proliferative response was measured
by 3H-thymidine incorporation. Results are expressed as a mean
(cpm) + SEM. a Mononuclear cells of spleens from BALB/c mice
treated with IDS 30 proliferated less than splenocytes from un-
treated animals after stimulation with LPS. This difference is
significant for the tested doses of LPS stimulation (1 mg/ml and
10 mg/ml LPS). b After stimulation, Peyer’s patches with LPS
(1 mg/ml and 10 mg/ml LPS) mononuclear cells from IDS 30-treated
animals proliferated less than those from untreated animals
(*p<0.05; **p<0.01; ***p<0.001)
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